Mineral cation complex compositions, formulations therof, and methods of use therof

Abstract

The disclosure provides compositions and formulations for the treatment and mitigation disease as well as the restoration of cells to a state of metabolic homeostasis. The disclosure further provides exemplary methods of administering a therapeutically effective amount of a composition or formulation comprising a mineral cation complex and ionic salt to a subject for the treatment of disease or disorder. The disclosure further provides exemplary methods of administering a therapeutically effective amount of a composition or formulation comprising a mineral cation complex and ionic salt to a subject for the maintenance or restoration of cellular metabolic homeostasis.

1 - 86 . (canceled) 
     
     
         87 . A method for treating Lyme Disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising hexaaquacopper ions, hexaaquazinc ions, hexaaquamagnesium ions, hydrogen cations, ammonium, hydrogen sulfate, and water. 
     
     
         88 . The method of  claim 87 , wherein the composition comprises hexaaquacopper ions in an amount of from about 1.0% to about 2.5% w/w 
     
     
         89 . The method of  claim 87 , wherein the composition comprises hexaaquazinc ions in an amount of from about 3.5% to about 5.0% w/w. 
     
     
         90 . The method of  claim 87 , wherein the composition comprises hexaaquamagnesium ions in an amount of from about 1.0% to about 2.5% w/w. 
     
     
         91 . The method of  claim 87 , wherein the composition comprises ammonium in an amount of from about 1.0% to about 2.5% w/w. 
     
     
         92 . The method of  claim 87 , wherein the composition comprises hydrogen sulfate in an amount of from about 18% to about 20% w/w. 
     
     
         93 . The method of  claim 87 , wherein the composition comprises water in an amount of from about 70% to about 71.5% w/w. 
     
     
         94 . The method of  claim 87 , wherein said treating further comprises treating a disorder secondary or co-morbid with Lyme Disease. 
     
     
         95 . The method of  claim 87 , wherein the composition is administered systemically. 
     
     
         96 . The method of  claim 87 , wherein the composition is administered orally, intranasally, intravenously, intraperitoneally, subcutaneously or intramuscularly. 
     
     
         97 . The method of  claim 87 , wherein the composition is administered locally. 
     
     
         98 . The method of  claim 87 , wherein the composition is administered topically, intraocularly, intraspinally, intracerebroventricularly, intraosseously or intratumorally. 
     
     
         99 . The method of  claim 87 , wherein the composition further comprises a pharmaceutically acceptable carrier. 
     
     
         100 . The method of  claim 87 , wherein the composition further comprises one or more botanical agent(s). 
     
     
         101 . The method of  claim 100 , wherein the one or more botanical agent(s) comprises Graviola ( Annona muricate ), Bitter Melon ( Momordica charantia ), Esplanheira Santa ( Maytenus illcifolia ), Mullaca ( Physolis angulate ), Vasourinho ( Scoparia dulcis ), Mutamba ( Guazuma ulmifola ), Suma ( Pfaffia paniculata ), Cat's Claw ( Uncaria tomantosa )and Blood Root ( Sanguinaria canadensis ). 
     
     
         102 . A formulation comprising the composition of  claim 87 , wherein the formulation is suitable for administration in a liquid form, a suspension form, a rehydrated form, a droplet form, an aerosol form, a vaporized form, a nebulized form, a semi-solid form, a solid form, a pill form, a tablet form or a capsule form. 
     
     
         103 . The method of  claim 87 , wherein the hexaaquacopper ions are hexaaquacopper (II) ions, the hexaaquazinc ions are hexaaquazinc (II) ions, and the hexaauqamagnesium ions are hexaaquamagnesium (II) ions. 
     
     
         104 . The method of  claim 87 , wherein the composition is administered by a nebulizer. 
     
     
         105 . The method of  claim 87 , wherein said treating further comprises alleviating Erythema migrans (EM)rashes, swollen lymph nodes, arthritis and swelling of joints, carditis and heart arrhythmia, neuritis, neurocognitive impairment, facial palsy, intermittent pain or paresthesia of the body, fever, fatigue, dizziness, and/or shortness of breath. 
     
     
         106 . The method of  claim 87 , wherein said treating further comprises treating Post-Treatment Lyme Disease Syndrome (PTLDS), chronic Lyme arthritis, and/or chronic Lyme neuroborreliosis.